Surufatinib Improves PFS in Advanced Pancreatic Neuroendocrine Tumors
Surufatinib improved progression-free survival compared with placebo in patients with low- or intermediate-grade advanced pancreatic neuroendocrine tumors for whom there is no effective therapy.
Source: OncLive